Connect with us

Published

on

The United States Food and Drug Administration (FDA) has approved suzetrigine, a non-opioid painkiller, for short-term pain management. This approval marks the first time in over two decades that a new pain relief mechanism has been introduced. Suzetrigine, which selectively targets sodium channels on pain-sensing neurons, has been developed as an alternative to opioids, which have been linked to addiction and overdose crises. The drug is expected to provide pain relief similar to opioids but without the associated risks of dependency, sedation, or overdose.

Targeting Sodium Channels for Pain Relief

According to research presented at a major anesthesiology conference last year, suzetrigine, now branded as Journavx, works by blocking the NaV1.8 sodium channel subtype, which plays a key role in transmitting pain signals. Unlike traditional sodium channel-blocking drugs like lidocaine, which act on all nine subtypes indiscriminately, suzetrigine is designed to target pain-sensing neurons specifically. This selectivity reduces side effects and allows the drug to be taken orally rather than requiring local application.

Clinical Trials and Effectiveness

In clinical trials, more than 80% of participants reported effective pain relief after surgery or injury. Trials on individuals undergoing procedures such as bunion removal and tummy tucks showed that suzetrigine provided pain relief comparable to opioid-based regimens, with fewer side effects. Paul White, an anesthesiologist at Cedars-Sinai Medical Center, stated to Nature, that increasing non-opioid options could significantly reduce opioid dependency.

Challenges and Future Prospects

Suzetrigine has been priced at $15.50 per pill, a cost that remains higher than generic opioids but is considered cost-effective given the expenses associated with opioid addiction treatment. While its effectiveness in chronic pain conditions remains uncertain, pharmaceutical companies are advancing similar drugs targeting sodium channels, aiming to expand non-opioid pain relief options.

Continue Reading

Science

Astrophotographer Captures Stunning “Raging Baboon Nebula” in Deep Space

Published

on

By

A stunning new image by Greg Meyer shows the “Raging Baboon Nebula” in Corona Australis, about 500 light-years away. Captured over 13 nights at Starfront Observatory in Texas, the photo reveals a baboon-like face formed by blue reflection nebulae and dark molecular dust.

Continue Reading

Science

Cambridge Team Uncovers Unexpected Quantum Behaviour in Non-Metal Organic Molecule

Published

on

By

Cambridge scientists have made a major leap in solar innovation by discovering a quantum effect in an organic molecule, P3TTM. This new material can convert light into electricity with unprecedented efficiency, potentially leading to the next generation of lightweight, flexible, and cost-effective solar power systems.

Continue Reading

Science

New Fossil Teeth Evidence Suggests Herbivorous Dinosaurs Preferred Nutrient-Rich, Textured Plants

Published

on

By

Using the calcium isotopes of a 150-million-year-old dinosaur’s teeth, the researchers have identified them as fussy eaters. The herbivorous dinosaurs chose their food based on nutrients and textures, not according to their heights.

Continue Reading

Trending